Oncoinvent ASA (7BG)
XDUS
Closed
Aug 24, 2026
Day's Range
7.2252 wk Range
1.79Overview - 7BG - Oncoinvent ASA
Key Statistics
Valuation
Enterprise Value
-169.90M
P/E (Trailing)
‪-0.05‬
Price / Book
‪0.03‬
EV / EBITDA
‪1.39‬
Profitability
Operating Margin
‪-673.03%‬
Return on Assets
‪-75.65%‬
Return on Equity
‪-105.97%‬
Ownership
Shares Outstanding
4.47M
Price stats
50-Day Avg
‪6.12‬
200-Day Avg
‪3.90‬
Peers - 7BG - Oncoinvent ASA
Peer Comparison
Compared with companies in Biotechnology listed on XDUS.
- 7BGXDUSOncoinvent ASA+75.21%52-week change-0.06P/E (Trailing)—Profit Margin
- 4E2XDUSRelmada Therapeutics Inc.+86.32%52-week change-2.62P/E (Trailing)—Profit Margin
- 3920XDUSSpyre Therapeutics, Inc.+84.40%52-week change-45.96P/E (Trailing)—Profit Margin
- 42ZXDUSRevolution Medicines Inc.+82.81%52-week change-30.12P/E (Trailing)—Profit Margin
- 87EXDUSDianthus Therapeutics Inc.+78.08%52-week change-22.38P/E (Trailing)—Profit Margin
- 5NRAXDUSNanobiotix S.A. American Depositary Shares+77.55%52-week change—P/E (Trailing)—Profit Margin
- 5NRXDUSNanobiotix S.A.+77.54%52-week change—P/E (Trailing)—Profit Margin
Profile Summary - 7BG - Oncoinvent ASA
About
Oncoinvent ASA is a Norwegian clinical-stage biotechnology company focused on developing radiopharmaceutical therapies for cancer treatment. Its lead product candidate, Radspherin, is an investigational alpha-radiation therapy using calcium carbonate microparticles loaded with the radionuclide radium-224. Designed for…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
